Tracking Coronavirus Vaccines In Human Trials

1 / 24
Coronavirus Vaccines In Human Trials
Coronavirus Vaccines In Human Trials

Vaccination is an effective method of gaining immunity against future attacks by deadly viruses, bacteria, and other disease-causing pathogens.

Developing a vaccine usually takes 10 to 15 years but there are exceptions. It took just four years to develop and secure approval for a mumps vaccine in 1948, and five years for the Ebola vaccine that was approved in December 2019.

Guess what! The development work of a COVID-19 vaccine is being carried out at warp speed.

Like drug development, the vaccine development process also has three phases of clinical testing – phase I in which the safety and the responses a vaccine candidate evokes in healthy volunteers, say in a group of 20 - 100 healthy persons, phase II trial which tests the vaccine candidate’s most common side effects and immune response in several hundred volunteers, and phase III, in which the vaccine candidate’s safety, efficacy and side effects are tested in hundreds or thousands of volunteers.

But given the situation we are in, the clinical phases that normally take years to complete have been compressed into months and weeks. Combining phase I and phase II or phase II and phase III trials into a single protocol is also one way of accelerating vaccine development.

Let’s take a look at the COVID-19 vaccines that are in clinical trial development.

We will keep updating this slideshow as and when new candidate vaccines enter human trials.